Interleukin-6 and chronic inflammation.
Arthritis Research & Therapy2006Vol. 8(Suppl 2), pp. S3–S3
Citations Over TimeTop 1% of 2006 papers
Abstract
Interleukin (IL)-6 is produced at the site of inflammation and plays a key role in the acute phase response as defined by a variety of clinical and biological features such as the production of acute phase proteins. IL-6 in combination with its soluble receptor sIL-6Ralpha, dictates the transition from acute to chonic inflammation by changing the nature of leucocyte infiltrate (from polymorphonuclear neutrophils to monocyte/macrophages). In addition, IL-6 exerts stimulatory effects on T- and B-cells, thus favoring chronic inflammatory responses. Strategies targeting IL-6 and IL-6 signaling led to effective prevention and treatment of models of rheumatoid arthritis and other chronic inflammatory diseases.
Related Papers
- Rheumatoid arthritis and astercantha longifolia.(1999)
- [Radiosynoviorthese in the treatment of patients with rheumatoid arthritis].(1990)
- → PMS14 Impact of Severity Index for Rheumatoid Arthritis on Health Care Costs and Utilizations in Patients With Rheumatoid Arthritis(2012)
- → Functional activity of phagocytic cells in patients with rheumatoid arthritis in combination with arterial hypertension: changes in the treatment process(2019)